1. Apoptosis
  2. MDM-2/p53

MI-773 

Cat. No.: HY-17493 Purity: >98.0%
Data Sheet SDS Handling Instructions

MI-773 is a new small molecule inhibitor of the MDM2-p53 interaction, binds to MDM2 with high affinity (Ki=0.88 nM) and blocks the p53-MDM2 interaction.

For research use only. We do not sell to patients.
MI-773 Chemical Structure

MI-773 Chemical Structure

CAS No. : 1303607-07-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $161 In-stock
5 mg $130 In-stock
10 mg $210 In-stock
50 mg $810 In-stock
100 mg $1500 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of MI-773:

    MI-773 purchased from MCE. Usage Cited in: Nat Chem Biol. 2017 Dec 4.

    HCT 116 cells are treated with 4, ent-4 and SAR405838 for 2 h and lysed for western blotting analysis probing for USP7, p53, p-Ser15-p53, p21, MDM2 and β-actin as indicated.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    MI-773 is a new small molecule inhibitor of the MDM2-p53 interaction, binds to MDM2 with high affinity (Ki=0.88 nM) and blocks the p53-MDM2 interaction.

    IC50 & Target

    Ki: 0.88 nM (MDM2)[1]

    In Vitro

    MI-773 potently induces expression of p53 and its downstream targets p21, MDM2, and induces phosphorylation of p53 (serine 392) in low passage primary human ACC cells. Notably, MI-773 induces a dose-dependent increase in the fraction of apoptotic ACC cells and in the fraction of cells in the G1 phase of cell cycle (P<0.05). Consequently, MI-773 causes apoptotic cell death[1]. MI-773 is an advanced synthetic small molecule inhibitor, displays high binding affinity against MDM2 (Kd=8.2 nM)[2].

    In Vivo

    MI-773 at 10 mg/kg modestly reduces the rate of tumor growth, whereas 100 mg/kg causes significant tumor regression. Control tumors reach an average of 1,000 mm3 at 20 days of treatment, compare to an average volume of 600 mm3 for the 10 mg/kg group and 30 mm3 for the 100 mg/kg group. Kaplan-Meier analysis shows an increase in tumor failure, define as two times increase in tumor volume as compared to pretreatment volume (P=0.044), for vehicle-treated mice when compare to mice treated with 100 mg/kg MI-773[1].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.7778 mL 8.8889 mL 17.7778 mL
    5 mM 0.3556 mL 1.7778 mL 3.5556 mL
    10 mM 0.1778 mL 0.8889 mL 1.7778 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [1]

    MI-773 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1].

    Sulforhodamine B or the WST-1 cytotoxicity assay are performed to determine the effect of MI-773 on ACC cell viability. Briefly, 1 to 3×103 UM-HACC cells are plated per well, and treated with 0 to 40 μM MI-773 for 24 to 96 hours. To assess apoptosis, 2×105 cells are plated in 60 mm3 dishes, attached overnight, and treated with 0 to 20 μM MI-773 for 72 hours. Cells are lysed with a hypotonic buffer and stained with propidium iodide. Primary low passage ACC cells (UM-HACC-5) are stably transduced with lentiviral vectors expressing shRNA-p53 or scrambled sequence control shRNA-C and selected with 1.0 μg/mL puromycin[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    MI-773 is prepared in polyethylene glycol-200 + D-α-tocopherol polyethylene glycol 1000 succinate (Mice)[1].

    Mice[1] To establish a patient-derived xenograft (PDX) model of ACC, human tumor fragments from the UM-HACC-5 patient are transplanted subcutaneously into the dorsal region of male severe combined immunodeficient (SCID) mice (CB.17.SCID). Two of six initial patient tumor fragments transplant, grow, and are retransplanted in vivo into new male or female mice for up to 12 passages. When tumors reach an average of 250 mm3, mice are randomized into groups and received either vehicle (polyethylene glycol-200 + D-α-tocopherol polyethylene glycol 1000 succinate), or treatment with 10, 50, or 100 mg/kg MI-773 daily by oral gavage. The ACCx6 and ACCx9 models are treated with vehicle or 100 mg/kg MI-773. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    562.5

    Formula

    C₂₉H₃₄Cl₂FN₃O₃

    CAS No.

    1303607-07-9

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 53 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    MI-773
    Cat. No.:
    HY-17493
    Quantity: